Targeted Therapy of Ewing's Sarcoma

Table 7

Anticipated future trials of targeted therapy for refractory and/or recurrent Ewing’s sarcoma (EWS).

Sponsor site	Drugs	Rationale	Comments	PI contact info
Merck/UTMDACC	MK-0646+ MK8669	IGF1R+/− mTOR	“up front” Rx; Phase II in development	Joseph Ludwig, MD [email protected] UTMDACC
Georgetown/UTMDACC	YK-4-279	EWS-FLI1: RNA helicase inhibitor	Currently preclinical; clinical at UTMDACC	Jeffery Toretsky, MD [email protected]; Pete Anderson MD, PhD [email protected]; Aung Naing, MD [email protected]